跳至主要内容
临床试验/JPRN-jRCT1031220022
JPRN-jRCT1031220022招募中未知

Therapeutic effect of nalmefene on alcohol-related liver disease: multicenter clinical trial (pilot study)

Ikejima Kenichi0 个研究点目标入组 15 人开始时间: 2022年4月14日最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 80age old(—)
性别
All

入选标准

  • 1) Outpatients aged 20 to 80
  • 2) Patients who have a heavy drinking habit exceeding 60 g / day for men and 40 g / day for women in terms of pure alcohol and meet the diagnostic criteria of the ICD-10 diagnostic guidelines for alcohol dependence syndrome
  • 3) Patients who did not abstain from alcohol after the pre-observation period (4 to 12 weeks) and had a serum GGT level of 100 IU / L or higher
  • 4) Patients who have written consent to participate in this study

排除标准

  • 1) Patients treated for viral hepatitis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis or metabolic liver disease)
  • 2) Patients with decompensated cirrhosis (Child-Pugh grade C)
  • 3) Patients who are taking contraindications of nalmefene such as opioids
  • 4) Patients with advanced or malignant tumor requiring treatment
  • 5) Pregnant or suspected pregnant, lactating patients
  • 6) Patients judged to be ineligible by a doctor

研究者

发起方
Ikejima Kenichi

相似试验